The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Kuz'mina U.Sh.
Institut biohimii i genetiki Ufimskiĭ nauchnyĭ tsentr RAN, Ufa
Zainullina L.F.
Institute of Biochemistry and Genetics Ufa Federal Research Center, Russian Academy of Scienses, Ufa, Russia
Vakhitov V.A.
Institute of Biochemistry and Genetics Ufa Federal Research Center, Russian Academy of Scienses, Ufa, Russia
Bakhtiiarova K.Z.
Bashkirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Ufa
Vahitova Ju.V.
Institut biohimii i genetiki Ufimskiĭ nauchnyĭ tsentr RAN, Ufa
The role of glutamate in the pathogenesis of multiple sclerosis
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8): 160‑167
Views: 2488
Downloaded: 72
To cite this article:
Kuz'mina USh, Zainullina LF, Vakhitov VA, Bakhtiiarova KZ, Vahitova JuV. The role of glutamate in the pathogenesis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry.
2019;119(8):160‑167. (In Russ.)
https://doi.org/10.17116/jnevro2019119081160
The results of recent studies indicate that the hyperactivation of the glutamatergic system plays an important role in the pathophysiology of multiple sclerosis (MS). In addition to the well-known direct toxic effect of the excessive extracellular level of the glutamate neurotransmitter on neurons, additional mechanisms of glutamate-induced cell damage have been described in the literature, including effects on oligodendrocytes, astrocytes, endothelial cells and immune cells. The study of these toxic effects will reveal the possible link between various pathological hallmarks of MS, such as axonal damage, oligodendrocyte death, demyelination, neurodegeneration, autoimmune reactions and dysfunction of blood-brain barrier. Understanding the mechanisms underlying the glutamate toxicity will contribute to the development of new therapeutic approaches for the diagnosis and treatment of patients with MS. This review focuses on the mechanisms that lead to an increase in the concentration of neurotransmitter glutamate and excitotoxicity in the context of the pathogenesis of this disease. Also the authors present the data on existing and currently developed medicines and therapeutic approaches to regulate the activity of the glutamatergic system.
Keywords:
Authors:
Kuz'mina U.Sh.
Institut biohimii i genetiki Ufimskiĭ nauchnyĭ tsentr RAN, Ufa
Zainullina L.F.
Institute of Biochemistry and Genetics Ufa Federal Research Center, Russian Academy of Scienses, Ufa, Russia
Vakhitov V.A.
Institute of Biochemistry and Genetics Ufa Federal Research Center, Russian Academy of Scienses, Ufa, Russia
Bakhtiiarova K.Z.
Bashkirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Ufa
Vahitova Ju.V.
Institut biohimii i genetiki Ufimskiĭ nauchnyĭ tsentr RAN, Ufa
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.